Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-122 Open-Label Extension in Psoriatic Arthritis
NCT02429895Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Oct 2015
- Primary completion
- May 2016
- Modality
- Bispecific Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of remtolumab in psoriatic arthritis (PsA), sponsored by AbbVie Inc.. Started Oct 2015; status: terminated.
02
Drugs
remtolumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02429895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429895.